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Many DNA adduct studies have been carried out in occupational groups that have been at a risk
of cancer based on epidemiological results relating to exposures decades ago. Even new
epidemiological publications on cancer cannot accurately address the effective exposures after
about 1970. This is one justification for biomarker studies. Another justification is exposures for
which epidemiological studies have not been conducted or have provided inadequate results, in
spite of suspicions raised by short-term or animal experiments. The modulation of environmental
carcinogenesis by host polymorphism in genes for xenobiotic metabolizing and DNA repair
enzymes is currently under extensive investigation. The studies relating phenotype/genotype to
cancer are presently extended to various end points that may be related to cancer such as DNA
adducts and cytogenetic damage. Adjustment for a metabolic phenotype or genotype may also
increase the precision in the measurement. Mutations in oncogenes and tumor suppressor genes
may give clues to the etiology of cancer. Environ Health Perspect 104(Suppl 3):459-464 (1996)
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Introduction
The use ofbiomarkers (defined as indicators
ofexposure, effect, and individual suscepti-
bility) is relatively recent. Many of the
methods used have not been extensively
validated and it is not known, in most
instances, to what extent the biomarkers
predict the risk ofmutation or cancer.
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In this paper we will review, subjec-
tively, some areas of biomarker research
that are familiar to us. The areas covered
include DNA adducts, adducts and muta-
tions, and mutations in oncogenes and
tumor suppressor genes, including their
products, oncoproteins. Mutation epi-
demiology, whether carried out through a
twin or a population registry or linked to a
cancer registry, may be a powerful source
of new patients for genetic analysis.
Because genes involved in familial cancer
may also operate in common cancers, a
large interest in these genes has developed.
DNA Adducts
In the future, the emphasis in DNA adduct
research should be on quantification of
specific adducts. For some 10 years, aro-
matic adduct profiles have been presented
in the literature. While serving a purpose
as a general adduct level, there is now a
need to improve the specificity of adduct
studies, aiming at criteria of general
analytical chemistry; however, because of
multiple steps of analysis, a great deal of
standardization is required. The most
straightforward approach is to use both
external and internal standards for the
adducts to be identified. This is not
feasible in exposures to complex mixtures
such as polycyclic aromatic hydrocarbons
(PAHs). The approach is more feasible to
adducts, which make only one main type
ofadduct.
Another kind ofgeneral problem with
adducts is the use of surrogate tissues
instead oftarget tissues. Furthermore, half-
lives ofadducts are largely unknown even
in surrogate tissues. A few studies have
addressed these problems.
Smoking is a known risk factor of
laryngeal cancer. Aromatic adducts of
laryngeal tissue obtained from surgery were
analyzed; there was a relationship to smok-
ing, most clearly in the tumor tissue. Both
tumor and normal laryngeal tissues showed
a correlation ofabout 0.9 to the total white
blood cells (1).
Smokers had elevated levels of 7-
methylguanine, particularly in their
lymphocyte DNA as compared to the
granulocyte DNA (2). The adduct levels
were highest in the bronchial DNA of
smokers, almost four times the level in
nonsmokers (3). In a small number of
smokers, both target (bronchial) and surro-
gate (lymphocyte) DNA were available,
showing a correlation of0.8.
Larynx tissue samples obtained from
surgery have also been assayed for
7-methylguanine-DNA adducts. There
was a relationship to smoking, and larynx
adduct levels were two times the level in
white blood cells. There was a modest cor-
relation only between 7-alkylguanines and
aromatic adducts.
In the latter part ofthis section, we will
discuss some examples ofhow the problems
of specificity and quantification can be
tackled on very different kinds ofexposures.
PAHAdducts
We have attempted to study the nature of
the aromatic adducts detected in the post-
labeled samples from Silesia, an industrial-
ized area ofPoland, which has been a focus
of our studies for years. The methods
applied with samples before postlabeling
included nuclease P1 treatment, butanol
extraction, and immunoaffinity chroma-
tography (IAC) using an antibody raised
against benzo[a]pyrene-modified DNA
(4). The results on IAC are shown in
Figure 1. The antibody binds benzo[a]py-
rene diol epoxide (BPDE)-modified deoxy-
guanosine 3'-monophosphate (dGMP),
a microsomally produced mixture of 10
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Figure 1. Binding of aromatic adducts by benzo[a]-
pyrene diol epoxide (BPDE)-DNA antibody. The bound
material was eluted with methanol. The ratio
bound:unbound is shown for BPDE-dGMP standards,
DNA reacted with 10 different PAHs in a microsomal
system, and human white blood cell DNA from Silesia,
showing coke workers with occupational exposure and
Silesians with environmental exposure, sampled in
summer and winter.
different PAH-DNA adducts, and DNA
obtained from lymphocytes ofcoke workers
(highly occupationally exposed to PAHs)
and Silesian residents (environmentally
exposed to PAHs). However, samples of
both coke workers and other Silesians
showed more binding by the IAC column
in the winter, a time of heavy exposure
to PAHs.
In high-performance liquid chromatog-
raphy (HPLC) analysis using a flow-
through radioactivity detector, typical
seasonal adduct peaks were noted; they
were particularly prominent in lymphocyte
DNA collected in the winter. These peaks
eluted in the area of PAH-DNA adducts,
giving additional support that the adducts
are PAH-like (5).
Another problem with complex mix-
tures is the difficulty in quantitating the
results. In an illustrative experiment, DNA
adducts of a number of3H-labeled PAHs
were prepared in a microsomal system and
used for optimization and measurements of
recoveries in the postlabeling assay. The
optimal labeling conditions for all tested
compounds were very similar. The recover-
ies varied from 3 to 60% among different
PAHs, indicating that the levels of these
adducts could be considerably underesti-
mated when analyzing human samples
from PAH-exposed populations (6).
Because we have found similar results with
an entirely different group ofcompounds,
we concluded that different adducts require
different conditions for optimal labeling
(7). Thus, the absence ofproper standards,
or unknown adducts, makes quantitative
interpretation of the postlabeling results
difficult, ifnot impossible.
Further methods and efforts are needed
to characterize the levels of adducts of
individual PAHs or other aromatic com-
pounds, which is a large task.
Alkenes
Gasoline is one of the most common
solvent vapors to which workers and the
general public are exposed. The exposure is
particularly to the volatile alkanes and
alkenes. Additionally, many ofthe compo-
nents of gasoline are found in vehicle
exhaust either because ofincomplete com-
bustion or because ofthe chemical reac-
tions taking place in engines. Incomplete
combustion also creates new types ofcom-
pounds that are not present, or only in
minor quantities, in gasoline. Typically
these are various PAHs, but aliphatic com-
pounds such as alkenes ( e.g., ethene,
propene, butadiene, isoprene) and various
aldehydes are also being formed. Fuel and
engine development has been focused on
the reduction of the polycyclic aromatic
compounds. Catalytic converters, on the
other hand, are effective in removing the
main part ofvolatile hydrocarbons from
engine exhaust; however, even in optimal
conditions, a fraction remains. In cold
starts and in malfunctioning converters,
a high proportion of hydrocarbons is
released unburned.
The concerns about the harmful effects
ofengine exhausts have traditionally been
focused on polycyclic aromatic compounds
(8,9). There has been increasing concern
about the effects ofalkenes such as ethene,
propene, butadiene, and isoprene because
their epoxides (metabolites in humans) are
carcinogenic (10). The present risk esti-
mates of environmental cancer ascribe
cancers approximately equally to butadiene
alone as to polycyclic aromatic matter,
including PAHs (11). It is projected that
butadiene is increasing overwhelmingly
over polycyclic compounds; in 2010, it is
estimated that butadiene alone will cause
approximately five times more cancer than
polycyclic material, based on a comparison
ofmotorvehicle exhausts (11).
The extraordinary carcinogenicity of
butadiene in rodents influences such pro-
jections (8); however, for this compound
human occupational data are also becom-
ing available (12). New carcinogenic
alkenes are still being detected. Isoprene,
an analogue of butadiene that possesses
two double bonds capable ofcross-linking
DNA has recently been found to be a
potent carcinogen in rodents (10). It can
be assumed that other dialkenes will be
found in vehicle exhaust that will alter the
risk estimates for particular compounds.
Effort should be focused on DNA binding
products of alkenes, including butadiene
and isoprene. The occupational groups
that are most heavily exposed include tank
truck drivers, tank ship unloaders, butadi-
ene manufacturing workers, and garage
workers. The method ofadduct detection
can rely on the newly developed postlabel-
ing technique for monoadducts (7), which
has been successfully used in studies of
experimental animals exposed to 1-alkenes
(Figure 2) (13).
UV-Adducts
For cross-links, the technique used for
cisplatinum and UV cross-links can be
applied (14,15). This modification ofthe
postlabeling technique (Figure 3) is neces-
sary because cross-linked dinucleotides
label vary poorly (14,15). In the modifi-
cation, a normal nucleotide is left on the
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Figure 2. Liver and lymphocyte alkene adduct levels in
rats exposed to 300 ppm of alkenes for 12 hr on 3 con-
secutive days. Data from Eide et al. (13).
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Figure 3. The scheme of postlabeling for cross-linked
adducts.o, radioactive phospate. Data from Forsti et
al. (14) and Bykov et al. (15).
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resulting in a number of labeled trinu-
cleotides. This kind ofmodification is so
far the only way to label cross-linked prod-
ucts. The results on excised human skin,
irradiated at approximately 310 nm, are
shown in Figure 4, analyzed by HPLC
radioactivity detection.
UV-Adducts and Mutations
The incidence ofmalignant melanoma and
other skin cancers has increased markedly
in many countries with primarily fair-
skinned populations (16). In Sweden the
incidence ofmalignant melanoma and non-
melanomatous skin cancer has increased
more than any type ofcancer, representing
4.5 and 3.2% annual increases during the
last 20-year time period, respectively.
Solar ultraviolet (UV)-irradiation is
thought to be an important cause of the
nonmelanomatous skin cancer, but it may
also contribute to melanoma (16). UVlight
has complex action on biological organisms
and is considered a complete carcinogen,
with both initiation and promotion capaci-
ties in model systems (16,17). UV irradia-
tion causes specific dipyrimidine adducts in
DNA that are likely to be related to the
mutagenicity and tumor-initiating potential
of UV light. Mammalian cells can repair
the adducts at various rates (18). The rela-
tionship between DNA repair and cancer is
illustrated by several skin diseases such as
xeroderma pigmentosum, in which repair
defect predisposes to skin cancer. Decreased










common skin tumors such as basal cell
carcinoma (18).
Specific UV-induced photoproducts
may be measured by the novel modification
of the 32P-postlabeling technique (15).
Further methods development involves
adaptation ofthe method to human skin in
situ. UV-induced adducts can be deter-
mined in parallel with mutation measure-
ments in the p53 gene. The assay of
UV-specific CC to TT mutations in the
p53 gene in human skin has been published
(19). CC to TT mutations in the p53 gene
are rare in internal organs, which implicates
UV as the main causative factor. The
codons conveying transforming properties
should be complemented with silent muta-
tions that give no growth advantage, thus
serving as measures ofmutation frequency.
UV-induced photoproducts caused
experimentally and through suntanning
can be studied in an early biologically
effective target dose in human skin of
healthy individuals and patients with skin
diseases. The in situ transformation ofthe
adducts, including those on the p53 gene,
to p53 mutations could be measured in
several codons as an early indication of
potential hazard for skin cancer in individ-
uals. This would tie different photoprod-
ucts to mutations that appear relevant to
skin cancers in healthy and predisposed
humans. Adducts indicate the target dose
at a level of a nucleotide in the p53 gene,
DNA repair indicates the efficiency
of damage removal, and p53 mutations
20 40
Retention time, min
Figure 4. Human epidermis exposed to UVB and analyzed by the method used for cross-links. Some
cyclobutane dimers (such asTT=C) and 6-4 photoproducts (such asTT-T) are shown in HPLC radioactivity
indicate fixation of damage as mutations
relating to cancer risk.
Mutation Studies in
Tumor Suppressor Genes
Many cancer-related genes are excessively
large (20). This applies to both tumor sup-
pressor genes (Table 1) and to many DNA
repair genes. Thus, the screening of the
retinoblastoma (Rb) gene with 27 exons
requires a huge number of polymerase
chain reactions (PCR) because only a few
hundred nucleotides can be accurately
assayed at one time. There are many up-
to-date methods used in the detection of
unknown mutations at the gene, mRNA,
and protein levels (21-28):
* direct sequencing
* denaturing/constant gradient gel elec-
trophoresis (DGGE/CDGE), <600 bp
* capillary electrophoresis (CDCE)
* ligation-mediated assay
* single-strand conformation polymor-
phism (SSCP), -300 bp
* chemical deavage, <2000 bp
* application ofmismatch repair enzymes
* protein truncation assays, large
* mRNAlevel
* functional tests.
Although protein truncation assays (24)
are powerful in detecting deletion and
frameshift mutations, they fail to detect
missense mutations.
It is of utmost importance to be able
to screen mutant species in a reliable and
fast fashion. The results would be helpful
in the analysis ofall mutations, irrespective
ofwhether mutations are inherited or
somatic and to the extent that the muta-
tions are scattered in different parts ofthe
genome. This would result in simplified
analysis of disease carriers in genetic dis-
eases if parental DNA samples are not
available and of samples from somatic
mutations in cancer patients, even in large
genes. The aim is to widen the main
bottleneck in the analysis ofmutations.
Capillary electrophoresis has been used
extensively in protein sequencing and
to some extent in DNA sequencing. The
Table 1. Sizes of some tumor supressor genes (in base
pairs) and ofthe encoded proteins.
\Jy] Gene Size, bp Exons Amino acids
p16 -2,000 3 148
60 p53 20,000 11 393
APC >100,000 15 2,843
Rb >100,000 27 928
>standard BRCA1 100,000 22 1,863
detection. Data from Ponder(20) and Hogervorst etal. (24).
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primary feature ofcapillary electrophoresis
is its high separation power, giving a
baseline separation of long nucleotide
sequences that differ in size by one
nucleotide only. For mutational analysis
the applications are new but essentially
analogous to single-strand conformation
polymorphism (SSCP) (25) or denaturant
gradient gel electrophoresis (DGGE) (26).
In the first application, genomic DNA
sequences are amplified, denatured, and
analyzed on capillary electrophoresis as
single-stranded molecules. In the second
application, dubbed constant denaturant
capillary electrophoresis (CDCE) (26),
melting profiles ofthe nucleotide sequences
are analyzed; it is important that the
sequence to be analyzed contain domains
melting both at high and low tempera-
tures. This ensures separation ofheterodu-
plexes containing mismatches identical to
DGGE but with a constant denaturant
concentration in the capillary. This is dif-
ferent from the SSCP type of analysis in
that the samples are analyzed as partially
melted heteroduplexes and not as single
strands. In both methods, the DNA is avail-
able for sequence analysis; however, experi-
ence with analysis ofcertain sequences with
capillary electrophoresis will lead to some
understanding ofthe types and locations of
the mutations. An extensive sequence
analysis is required before the ground rules
can be established.
We used the 19 commonly found ras
mutants cloned in a plasmid, (Figure 5)
(27). We have devised primers that allow
us to use SSCP- and DGGE-type capillary
electrophoresis and sequences ofdifferent
lengths in order to compare the separation
power of the two methods. Most of the
mutations could be detected as homo-




Cellular growth signaling can be divided
into four separate stages: a) extracellular
growth factors (e.g., platelet-derived
growth factor [PDGF], epidermal growth
factor [EGF], and transforming growth
factor-a [TGFa]); b) growth factor recep-
tors at cell membranes (e.g., PDGF recep-
tor and a common receptor for EGF and
TGFla); c) intracellular signaling proteins,
G-proteins that interact between the mem-
brane receptors and nuclear processes.
(these forms involve many multistep path-
ways and include proteins such as ras [p21]
and raf); d) nuclear factors of many
functions such as transcription factors, cell-
cycle control proteins, and DNA repair
proteins, which have many interactions.
p53 protein appears to take part in each of
these functions.
The a-tocopherol, ,-carotene (ATBC)
cancer-prevention-trial serum bank includ-
ing 30,000 middle-aged smoking men can
be used to identify the possible association
between the level of growth factors and
oncoproteins (jointly called oncoproteins)
in respect to lung and colorectal cancer.
The cancer types were selected because of
their high incidence and known increase in
mutations or elevation of oncoproteins
(29-31). The oncoproteins selected
included rasp21 protein, p53 protein, and,
for squamous lung cancer only, epidermal
growth factor receptor (EGFR). The spe-
cial advantage ofthis study, as compared to
others carried out in this field, is the large,
well-characterized study population, which
enables the assessment ofthe oncoproteins
years before clinical diagnosis. Interview
data and serological analysis enable the
control for confounding variables.
The objectives ofthis work are 4-fold.
One objective is to analyze more thor-
oughly the role of oncoproteins in early
stages ofcancer. Evaluation ofthe lag time
between detection ofoncoproteins in serum
and clinical diagnosis of cancer can be
assessed in a large number ofcancers devel-
oped in this population. A second objective
is to analyze the prognostic value because
many oncoproteins are already being used
for prognostic purposes in the treatment of
cancer (32,33). As a third objective, the
appearance and possible fluctuation ofthe
levels ofoncoproteins provide information
about irreversibility, which is mechanisti-
cally important. And fourth, the variables
affecting the normal levels ofoncoproteins
will also become available.
For predictive and preventive purposes,
it is important to develop markers either
for general population screening or screen-
ing of some risk groups. The criteria of
predictivity are well established in general
population screening; this generally implies
that both false positive (low specificity) and
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Figure 5. Analysis of ras exon (codon 12) as wild type (GGT) and mutant (AGT) homoduplexes (A) and heterodu-
plexes (B) by constant denaturant capillary electrophoresis at72°C. Data from Kumar et al. (28).
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the marker. Based on the multiple pathways
to oncogenesis, it would be overly opti-
mistic to assume that one or a few onco-
protein markers would fulfill the criteria
for population screening. However, onco-
protein screening may serve a purpose in
the case of special groups such as those
seeking medical advice about their symp-
toms, families with a high incidence of
cancer, or tobacco smokers or other heavily
exposed populations. In such cases, the cri-
teria ofpopulation screening do not hold,
and the tolerance in predictivity can be
lower (34). The direction offalse diagno-
sis largely depends on the individual situa-
tion. Yet, it is important that diagnostic
efficiency is maintained, for example, the
cost-benefit is reasonable.
Genetic Epidemiology
Studies have been initiated with the
Swedish Cancer Registry (-1.2 million
patients) and the Twin Registry (-50,000
twin pairs) to analyze familial cancer in the
Cancer Registry, which covers all of
Sweden since the 1950s (Figure 6) and to
find out to what extent mono- and het-
erozygotic twins are presented in the
Registry. Because the Swedish Cancer
Generation registry Cancer registry




Figure 6. A scheme for using a population register
covering 3 to 4 generations linked to a cancer register
to detect families with unusual frequencies of cancer.
Registry is one of the largest in the world
and the Twin Registry is the largest, these
data sources will provide unique patient
material for analysis of common cancers
using sib pair analysis. However, as the col-
lection ofmaterial involves several genera-
tions, including a large number of dead
persons, logistics have to be worked out for
the identification of important genes in
common cancers.
Conclusions
This work uses a number of parameters
that are currently available to predict the
health outcome of the exposures of
concern (Figure 7). As emphasized by the






1960 1970 1980 1990
Figure 7. Use of biomarkers to estimate effects of
recent exposures as contrasted to epidemiological data
in which relevant exposures usually occurred decades
earlier. Three kinds of exposure patterns are shown.
The relevant periods for biomarkers are indicated
on top.
proponents ofmolecular epidemiology, the
present-day findings can be translated to
risk estimates in the absence ofepidemio-
logical data (35). The relevant exposure
data from epidemiological studies date
decades back and are usually uncertain (see
Figure 7); this impedes direct extrapolation
to the risks of the current exposure.
Furthermore, individual metabolic factors
can be taken into consideration.
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